Patient info Search Menu

Sodium Glycerophosphate 21.6% concentrate for solution for infusion – patient leaflet, side effects, dosage

Updated:
Medicine strength:
21.6%
Contains active substance:

Patient leaflet - Sodium Glycerophosphate 21.6% concentrate for solution for infusion

1. What Sodium Glycerophosphate is and what it is used for

Sodium Glycerophosphate provides salts into your blood stream when you cannot eat normally. Sodium Glycerophosphate is usually used as part of a balanced intravenous diet, together with proteins, fats, carbohydrates, and vitamins.

2. What you need to know before you use Sodium Glycerophosphate

Do not use Sodium Glycerophosphate

  • if you are allergic to sodium glycerophosphate or any of the other ingredients of this medicine (listed in section 6).
  • if you are suffering from shock
  • if you are dehydrated (there is not enough water in the body)
  • if you have high levels of sodium, phosphate or potassium in your blood
  • if you have any problems with your kidneys

    PACKAGE LEAFLET: INFORMATION FOR THE PATIENT

Sodium Glycerophosphate 21.6% concentrate for solution for infusion

Sodium Glycerophosphate should be added to another solution before it is given to you. Your doctor, pharmacist or nurse will make sure it is prepared correctly before you receive Sodium Glycerophosphate.

Warnings and precautions

You should not receive this medicine undiluted.

Talk to your doctor, pharmacist or nurse before using Sodium Glycerophosphate

  • if you suffer from impaired liver function

Your doctor may want to do regular blood tests to check your condition.

Other medicines and Sodium Glycerophosphate

Tell your doctor, pharmacist or nurse if you have been administered carbohydrate infusions or if you are taking, have recently taken or might take any other medicines.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant to are planning to have a baby, ask your doctor, pharmacist or nurse for advise before using this medicine.

Driving and using machines

Sodium Glycerophosphate has no effect on the ability to drive or use machines.

3. How to use Sodium Glycerophosphate

You will receive your medicine by infusion (IV drip).

Your doctor will decide on the correct dose for you to receive.

Dosage

Adults

The recommended daily dosage is 10-20 ml Sodium Glycerophosphate, added to your infusion solution. Sodium Glycerophosphate will usually be given every day until you can start eating again.

If you receive more Sodium Glycerophosphate than you should

It is very unlikely that you will receive more infusion than you should as your doctor or nurse will monitor you during the treatment. However if you think that you have received too much Sodium Glycerophosphate inform your doctor or nurse as soon as possible.

If you have any further questions on the use of this product, ask your doctor, pharmacist or nurse. 650

What Sodium Glycerophosphate looks like and contents of the pack

Sodium Glycerophosphate is a clear, colourless solution containing phosphate and sodium. It is available in plastic vials and ampoules. Each vial and ampoule of Sodium Glycerophosphate contains 20 ml of the undiluted solution.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

Fresenius Kabi Limited,

Cestrian Court

Eastgate Way

Manor Park

Runcorn

Cheshire

WA7 1NT, UK

Manufacturer:

Fresenius Kabi Norge AS

NO-1753 Halden

Norway

This leaflet was last revised in June 2018

01-58-07-029 V004

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everyone gets them.

If you develop a rash or other allergic reactions (like itching, swollen lips or face or shortness of breath), please inform your doctor, pharmacist or nurse.

No known undesirable effects have been reported with the use of Sodium Glycerophosphate.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in this leaflet.

You can report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Sodium Glycerophosphate

Keep out of the sight and reach of children.

Your doctor and hospital pharmacist are responsible for the correct storage, use and disposal of Sodium Glycerophosphate infusion. Do not store above 25 ºC. Do not freeze.

Do not use this medicine after the expiry date which is stated on the carton and vial and ampoules labels. The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Sodium Glycerophosphate infusion contains

1 millilitre of Sodium Glycerophosphate contains the following active ingredients:

306.1 mg Sodium glycerophosphate pentahydrate which is equivalent to 216 mg sodium glycerophosphate. This provides 1 mmol phosphate and 2 mmol sodium per ml.

Sodium Glycerophosphate also contains hydrochloric acid and water for injections.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk)

Last revision stated in the text: June 2018

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Sodium Glycerophosphate 21.6% concentrate for solution for infusion

What these facts mean

Active substance? Sodium glycerophosphate
Strength? 21.6%
Excipients? Hydrochloric acid, Water for Injections
Shelf life? 36 months
Storage Do not store above 25°C. Do not freeze. From a microbiological point of view, the product should be used immediately.
Marketing authorisation? PL 08828/0147 (first authorised 28 July 2003)
Marketing authorisation holder? Fresenius Kabi Limited

Sources: the MHRA product information (products.mhra.gov.uk). Contains public sector information licensed under the Open Government Licence v3.0.